Evidence map›Paper›PMID 33460282›Full record

ReviewProteomics2021

Mass spectrometric investigations of caloric restriction mimetics.

Michael J Bibyk, Melanie J Campbell, Amanda B Hummon

Open access · greenAbstract readReview
In one paragraph

Review in Proteomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael J BibykOhio State Biochemistry Program, The Ohio State University, Columbus, Ohio, USA.
Melanie J CampbellDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio, USA.
Amanda B HummonOhio State Biochemistry Program, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0002-1969-9013
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Spatial SILAC: Examining the Proteome in 3D Cell CulturesR01GM110406 · NIGMS · UNIVERSITY OF NOTRE DAME · PI HUMMON, AMANDA B. · 2014 to 2022
$3.0M
NCI NIH HHS P30 CA016058NIGMS NIH HHS R01 GM110406NIGMS NIH HHS R01-GM110406
6 · The paper itself

Abstract

Caloric restriction (CR) is an innovative therapy used in tumor tissue and tumor model studies to promote cell death and decrease cell viability. Caloric restriction mimetics (CRMs) are a class of drugs that induce CR and starvation conditions within a cell. When used simultaneously with other chemotherapy agents, the effects are synergistic and effective at promoting tumor cell death. In this review, we discuss CRMs and their potential as cancer therapeutics. Firstly, we establish an overview of CR and its impacts on healthy and tumor cells. CR and CRM drugs have shown to decrease age-related diseases and can act as an anti-cancer agent. As it can be challenging for an individual to diligently stick to a diet that would induce CR, CRMs are even more desirable. Then, we discuss the drug class by highlighting three CRMs: resveratrol, (-)-hydroxycitric acid, and rapamycin. These CRMs are commonly known for their dietary effects, but the underlying mechanisms that drive cellular metabolic and proteomic changes show promise as a cancer therapeutic. Lastly, we highlight the use of mass spectrometry and proteomic techniques on experiments utilizing CRM drugs to understand the cellular pathways impacted by this drug class, leading to a better understanding of the anti-cancer properties and potentials of CRM.

Indexed as

Caloric RestrictionProteomicsMass SpectrometrySirolimusSirolimusanti-cancercaloric restrictioncaloric restriction mimetichydroxycitric acidmass spectrometryproteomicsrapamycinresveratrol

Identifiers

PMID33460282
PMCPMC8262777
OpenAlexW3125158192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.